// Account brief

AstraZeneca

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 7 6 scaled 5 6
Research labs and data 5 4 live 0 8

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

AstraZeneca says over 90% of its small-molecule discovery pipeline is AI-assisted, and that it is building foundation models and agentic AI frameworks for drug discovery. AI in drug discovery scores 7 out of 10 for priority and 6 for delivery, at the scaled stage, because the company states that share across its small-molecule portfolio. Research labs and data scores 5 for priority and 4 for delivery: its Kendall Square R&D centre opened with ten floors of labs that integrate robotics, continuous automation and agentic AI. In the last 12 months AstraZeneca made five AI commitments public, including the AISB Bind federated model, the LIGAND-AI consortium and the Illumina Billion Cell Atlas, against three in the year before; we identified no research labs and data commitment in either year. On 6 October 2026 it had 6 open R&D roles in AI in drug discovery and 8 in research labs and data, and the sources name tools in use such as AWS, Snowflake, Domino, NVIDIA DGX SuperPOD and Claude Code.

AI in drug discovery

What the company says: Priority 7

we are investing significantly in transformative technologies that will shape the future of medicine ... This includes harnessing the power of AI where, for example, 90% of our small molecule discovery pipeline is already AI-assisted

AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 7

Our $2.5 billion investment expands early discovery and development and incorporates an AI and data science laboratory.

AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 7

In R&D, we are developing an ecosystem of foundation models and AI agentic frameworks to accelerate our drug discovery

AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 38

What it shows running: Delivery 6, scaled

Over 90% of our small molecule discovery pipeline is AI-enabled, with similar approaches actively applied to other areas, including biologics.

AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 38

90% of our small molecule discovery pipeline is enabled by AI

AI & data in Drug Discovery & R&D (corporate R&D page), Aug 2026

Delivered industry-leading genomic insights while remaining sustainable, redesigning algorithms that cut CO2 emissions and compute time by 99.8% compared to global standards.

AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 30

These efficiencies have achieved a more than 99% reduction in compute time and CO2 emissions compared to current industry standards.

Our Sustainability Impact 2026 (sustainability impact publication), 29 Apr 2026, p. 19

REINVENT, our small molecule discovery platform now enables significant time savings by predicting molecular properties and optimising potential molecules before synthesis and further development.

AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 38

Commitments made public in the last 12 months: 5

Commitments made public in the year before: 3

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 6

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: AWS, Claude Code, Claude Cowork, Confluence, Domino, GitHub, GitHub Copilot, Hugging Face, Kubernetes, M365 Copilot, NVIDIA DGX SuperPOD.

Asked for as experience: GitHub Actions.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Research labs and data

What the company says: Priority 5

The R&D centre includes ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AI.

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026

AstraZeneca today announced the opening of its newest global strategic research and development (R&D) centre, in Kendall Square

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026

ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AI

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026

What it shows running: Delivery 4, live

AstraZeneca today announced the opening of its newest global strategic research and development (R&D) centre, in Kendall Square

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026

The R&D centre includes ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AI.

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026

$171m expense within Research and development expense in relation to severance as well as the transformation of clinical, regulatory and other R&D data and systems.

AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 144

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 0

None identified in the reviewed sources.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 8

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: AWS, PostgreSQL, Snowflake, Claude Code, Claude Cowork, Confluence, Domino, GitHub, GitHub Copilot, Hugging Face, Kubernetes, M365 Copilot.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Two questions to investigate (Ortent's interpretation)

  1. AstraZeneca's Enterprise AI unit, created in December 2025, is to deliver a single data foundation, while R&D runs its own platforms, such as a drug discovery data platform on AWS and a biobank and LIMS system. Who decides on additions to these platforms, and how do lab systems connect to the single data foundation?
  2. Four of the five AI commitments made public in the last 12 months came through joint, partner or consortium releases. Which function decides on joining outside AI discovery collaborations, how does it work with the Enterprise AI unit and the Centre for Genomics Research, and how are outside discovery tools evaluated, bought and funded?

Coverage limits

The astrazeneca.com press release listing is built by script and could not be listed, so the newsroom was covered only through individual releases and searches, and every search area is rated partial. The SEC site refused automated access, no results call transcripts were searched, and the FY2026 annual report does not exist yet, so the last 12 months rest mainly on the FY2025 annual report and results materials. Revvity Signals, Tempus and Fierce Biotech blocked access, and a vendor case study on an AstraZeneca electronic lab notebook could not be verified and is not used. Job postings came from a screened set of archived pages, not a full count.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call